Bombay Metrics (BMETRICS)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Low trailing P/E of 12.17 offers a modest valuation if earnings stabilise.
• ROCE of 29.41% suggests efficient use of capital in current operations.
• Promoter holding at 70.13% aligns management interests with minority shareholders.
• A small 0.54% dividend yield provides some minor shareholder return.

Concerns

• Profit growth down 38.67% and sales down 3.32% show deteriorating fundamentals.
• Piotroski F-score of 3/9 points to weak financial health.
• Latest quarterly net margin is razor-thin at ₹1 crore profit on ₹46 crore sales.
• Trading and distribution business likely lacks a durable competitive moat; debt and book value data are missing.

AI Analysis

At first glance, Bombay Metrics looks cheap at ₹40.90 with a P/E near 12 and a market cap of just ₹46 crore. But cheap can be a trap. This is a trading and distribution business, a segment I generally avoid because it rarely has an economic moat. The figures confirm my caution: sales declined 3.32% and profit fell 38.67%. In the latest quarter, the company generated ₹46 crore in sales but only ₹1 crore in net profit—a razor-thin margin. That tells me this is a low-margin operation where competition can quickly erode returns. The ROCE of 29.41% looks impressive, but with book value and debt data unavailable, I cannot verify how sustainable that is. The Piotroski F-score of 3 out of 9 is a red flag; it suggests deteriorating financial health across profitability, leverage, or efficiency metrics. Promoter holding of 70.13% is a positive—owners have skin in the game—but it also means minority float is small and liquidity may be poor. A 0.54% dividend yield is not meaningful. At a 52-week range of ₹33.30 to ₹56.90, the stock is in the lower half, but a falling knife is not automatically a bargain. As Graham would say, price is what you pay, value is what you get. Here, I struggle to identify value beyond the low P/E. I need years of consistent earnings, a moat, and trustworthy financials. This has none of that. I'll pass unless the next few quarters show stabilisation and honest improvement in margins and profit growth.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer